Cargando…

Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial

BACKGROUND AND OBJECTIVES: The oral calcitonin gene–related peptide receptor antagonist atogepant is indicated for the preventive treatment of episodic migraine. We evaluated changes in patient-reported outcomes with atogepant in adults with migraine. METHODS: In this phase 3, 12-week, multicenter,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lipton, Richard B., Pozo-Rosich, Patricia, Blumenfeld, Andrew M., Li, Ye, Severt, Lawrence, Stokes, Jonathan T., Creutz, Lela, Gandhi, Pranav, Dodick, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984220/ https://www.ncbi.nlm.nih.gov/pubmed/36396451 http://dx.doi.org/10.1212/WNL.0000000000201568

Ejemplares similares

Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial
por: Lipton, Richard B., et al.
Publicado: (2022)

Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial
por: Schwedt, Todd J, et al.
Publicado: (2021)

Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial
por: Ashina, Messoud, et al.
Publicado: (2023)

Atogepant for the prevention of episodic migraine in adults
por: Switzer, Maranda Paige, et al.
Publicado: (2022)

Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations
por: Cohen, Fred, et al.
Publicado: (2022)

Novel Oral CGRP Receptor Antagonist Atogepant in the Prevention of Migraine
por: Chowdhury, Selia, et al.
Publicado: (2023)

Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials
por: Blumenfeld, Andrew M., et al.
Publicado: (2021)

The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials
por: Tao, Xinyu, et al.
Publicado: (2022)

Development and validation of a novel patient‐reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary
por: Lipton, Richard B., et al.
Publicado: (2021)

Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies
por: Pozo-Rosich, Patricia, et al.
Publicado: (2022)

Atogepant for the Prevention of Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Efficacy and Safety
por: Lattanzi, Simona, et al.
Publicado: (2022)

The Role of Glial Cells in Different Phases of Migraine: Lessons from Preclinical Studies
por: Vila-Pueyo, Marta, et al.
Publicado: (2023)

OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT
por: Dodick, D, et al.
Publicado: (2013)

EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study
por: Goadsby, P, et al.
Publicado: (2014)

Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults
por: Min, K. Chris, et al.
Publicado: (2020)

Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition
por: Diener, Hans-Christoph, et al.
Publicado: (2019)

Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA
por: Torres-Ferrus, Marta, et al.
Publicado: (2020)

Migraine headache is present in the aura phase – a prospective study
por: Hansen, JM, et al.
Publicado: (2013)

Efficacy, Tolerability, and Safety of DFN‐15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study
por: Lipton, Richard B., et al.
Publicado: (2019)

Impact of headache frequency and preventive medication failure on quality of life, functioning, and costs among individuals with migraine across several European countries: need for effective preventive treatment
por: Buse, Dawn C., et al.
Publicado: (2023)

Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial
por: Ailani, Jessica, et al.
Publicado: (2020)

Single‐Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial
por: Boinpally, Ramesh, et al.
Publicado: (2021)

Non-invasive neuromodulation for migraine and cluster headache: a systematic review of clinical trials
por: Reuter, Uwe, et al.
Publicado: (2019)

Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension
por: Lipton, Richard B, et al.
Publicado: (2020)

Impact of Puberty in Pediatric Migraine: A Pilot Prospective Study
por: Fonseca, Elena, et al.
Publicado: (2020)

Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double‐Blind, Placebo‐Controlled, Multicenter Trial
por: Yarnitsky, David, et al.
Publicado: (2019)

Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial
por: Diener, Hans-Christoph, et al.
Publicado: (2019)

The premonitory phase of migraine is due to hypothalamic dysfunction: revisiting the evidence
por: Gollion, Cedric, et al.
Publicado: (2022)

OnabotulinumtoxinA: An Effective Tool in the Therapeutic Arsenal for Chronic Migraine With Medication Overuse
por: Caronna, Edoardo, et al.
Publicado: (2018)

Adding eptinezumab to brief patient education to treat chronic migraine and medication-overuse headache: Protocol for RESOLUTION—A phase 4, multinational, randomized, double-blind, placebo-controlled study
por: Jensen, Rigmor H., et al.
Publicado: (2023)

Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial
por: Croop, Robert, et al.
Publicado: (2022)

Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications
por: Goadsby, Peter J, et al.
Publicado: (2020)

Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society
por: Diener, Hans Christoph, et al.
Publicado: (2021)

Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants
por: Ankrom, Wendy, et al.
Publicado: (2020)

Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons
por: Melo-Carrillo, Agustin, et al.
Publicado: (2020)

Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial
por: Boinpally, Ramesh, et al.
Publicado: (2021)

Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study
por: Lipton, Richard B., et al.
Publicado: (2019)

EHMTI-0270. Experience with onabotulinumtoxin type a in high-frequency episodic migraine
por: Pozo-Rosich, P, et al.
Publicado: (2014)

EHMTI-0283. Predictors of early response to onabotulinumtoxin type a in chronic migraine
por: Mas-Sala, N, et al.
Publicado: (2014)

Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
por: Caronna, Edoardo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eafpshtssf3gccags84omnbfc8